LOXL3

Across TCGA pan-cancer cohorts, LOXL3 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of LOXL3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where LOXL3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LOXL3 is over-expressed in tumor, although a few such as KICH and BLCA show the opposite, repressed pattern.

HNSC, KIRC, and KICH are the cancer types where LOXL3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LOXL3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.146	<.001	12	view →
KIRC	Male	IV	+1.115	<.001	11	view →
KICH	All	II,III,IV	−0.784	<.001	7	view →
COAD	All	II,III,IV	+0.344	.002	6	view →
BRCA	Female	All	+0.314	<.001	6	view →
CHOL	All	All	+1.198	<.001	5	view →
LIHC	Female	All	+0.413	<.001	5	view →
STAD	Male	II,III,IV	+0.704	.019	4	view →
ESCA	Male	All	+1.323	.018	2	view →
BLCA	Male	IV	−1.072	.016	2	view →
PRAD	All	All	−0.250	.045	2	view →
KIRP	All	All	+0.400	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

LOXL3–HNSC

Open the HNSC breakdown →